AAX Biotech Secures Investment from Trio Impact Invest for Antibody Technology Development
AAX Biotech has received an investment from Trio Impact Invest AB to support the development and scaling of its antibody technology platforms. This funding will facilitate expanded applications and strengthen industry collaborations, including a partnership with Daiichi Sankyo. The investment reflects AAX Biotech's recent technological and commercial advancements.
Theia Market Signal Identification - AI Assisted
AAX Biotech has announced an investment from Trio Impact Invest AB to further develop and scale its antibody technology platforms. This funding aims to enhance platform capabilities and foster industry collaborations, following the company's progress in automation and partnerships, notably with Daiichi Sankyo. The investment will focus on advancing the platforms and building on existing partnerships, marking a significant step in AAX Biotech's growth strategy.
Comments